BiotechTube
Home/Pipeline/iTOL-401

iTOL-401

Not Specified

PreclinicalActive (subject to license)

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active (subject to license)
Company
iTolerance

About iTolerance

iTolerance is a private, preclinical-stage biotech founded in 2020 and based in Miami, Florida. The company's mission is to eliminate the need for chronic immunosuppression in regenerative medicine through its proprietary iTOL-100 immunomodulatory platform, which utilizes a synthetic FasL protein. Its lead programs, iTOL-101 and iTOL-102, aim to cure Type 1 Diabetes using allogeneic cadaveric islets and stem cell-derived islets, respectively, and have shown promising preclinical results in non-human primates. The company is also exploring other applications, including a liver program (iTOL-201) and a potential program for ovarian insufficiency (iTOL-401).

View full company profile

Therapeutic Areas

Type 1 DiabetesLiver Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved